THE MEASUREMENT OF SERUM AND PLASMA-DERIVED SUBSTANCE P

血清和血浆衍生物质P的测定

• 批准号: 7349118
• 负责人: D E CAMPBELL
• 金额: $ 3.1万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349118
• 关键词: MEASUREMENT; SERUM; PLASMA; DERIVED; SUBSTANCE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The undecapeptide substance P (SP) is a member of the tachykinin family of neurotransmitters which has a pivotal role in the regulation of inflammatory and immune responses. The demonstration of elevated levels of plasma SP in a number of immune disorders, including rheumatoid arthritis and the acquired immune deficiency syndrome, has led to increased interest in mechanisms of action involving key effector cells of the immune system and components of the neurokinin pathways. There have been several investigations into the interaction of SP with its preferred receptor (NK1-R), as well as, studies directed toward the development of several SP antagonists as potential immunoregulatory agents. Central to such studies is the accurate measurement of substance P in fluids. There is variability in the reported levels in humans of serum and plasma-derived SP in both healthy and diseased states. This study was initiated in order to identify sources of variability by the comparative evaluation of the influence of sample preparation and analytical detection methods on the measurement of serum and plasma-derived SP. The results indicate that sample preparation (peptide extraction vs no extraction) and choice of analytical method for SP quantitation can yield significantly different values and may contribute to the variability observed in the literature. The results further emphasize the need for careful consideration in the selection of methods used for SP quantitation, as well as caution in the interpretation and comparison of data reported in the literature.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。肽P（SP）是神经递质的速素家族的成员，该家族在调节炎症和免疫反应的调节中具有关键作用。在包括类风湿关节炎和获得的免疫缺陷综合征在内的多种免疫疾病中血浆SP升高的证明，导致人们对涉及免疫系统关键效应细胞和神经蛋白素途径的组成部分的作用机理的兴趣增加。已经对SP与其首选受体（NK1-R）的相互作用进行了几项研究，以及针对多种SP拮抗剂作为潜在免疫调节剂的发展的研究。这种研究的核心是对流体中物质P的准确测量。在健康和患病状态下，血清和血浆衍生的SP人类报告的水平有差异。 这项研究的开始是为了通过比较样品制备和分析检测方法对血清和血浆衍生SP的测量的影响来识别可变性的来源。结果表明，样品制备（肽提取与无提取）和SP定量分析方法的选择可以产生明显不同的值，并且可能有助于文献中观察到的可变性。结果进一步强调了在选择用于SP定量方法的方法时需要仔细考虑的，以及在文献中报道的数据的解释和比较时要谨慎。